Guangxi Wuzhou Zhongheng Group (SHA:600252) received approval from China's National Medical Products Administration to amend some information of its drug, clindamycin phosphate injection, after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange filing on Saturday.

Some of the changes included amending the modification to the drug formula and its manufacturing process and revising the drug quality standards.

The drug is mainly used to treat serious infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, staphylococci, and other designated sensitive microorganisms, the Chinese drugmaker said.

The company's shares closed less than 3% higher.